Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Student fatally shot, suspect detained at Georgia's Kennesaw State University
AI tech helps in early detection of pancreatic cancer
New plant species discovered in SW China
Monster Georgia father is sentenced to 50 years in prison for poisoning his 18
Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
2023 Beijing Culture Forum to be held
Megan Fox shows off new blue hair as she arrives to Coachella party in Daisy Dukes and sexy thigh
Ravens sign WR Qadir Ismail, the son of former NFL receiver Qadry Ismail
Chinese tech firms strive for leadership in global e
I visited the most crowded island on Earth
Chinese scientists develop ultrastrong, high thermal insulating ceramics